CLINICAL TRIALS PROFILE FOR ROCALTROL

All Clinical Trials for ROCALTROL

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000412 ↗	Osteoporosis Prevention After Heart Transplant	Completed	Merck Sharp & Dohme Corp.	Phase 3	1997-09-01	During the first year after a heart transplant, people often rapidly lose bone from their spine and hips. About 35 percent of people who receive heart transplants will suffer broken bones during the first year after transplantation. This study will compare the safety and effectiveness of the drug alendronate (Fosamax) and the active form of vitamin D (calcitriol) in preventing bone loss at the spine and hip after a heart transplant. In this study, people who have had a successful heart transplant will receive either active alendronate and a "dummy pill" instead of calcitriol, or active calcitriol and a dummy pill instead of alendronate for the first year after their transplant, starting within 1 month after transplant surgery. We will measure bone density in the hip and spine at the start of the study and after 6 and 12 months, and will also check for broken bones in the spine. This research should lead to ways of preventing this crippling form of osteoporosis.
NCT00000412 ↗	Osteoporosis Prevention After Heart Transplant	Completed	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)	Phase 3	1997-09-01	During the first year after a heart transplant, people often rapidly lose bone from their spine and hips. About 35 percent of people who receive heart transplants will suffer broken bones during the first year after transplantation. This study will compare the safety and effectiveness of the drug alendronate (Fosamax) and the active form of vitamin D (calcitriol) in preventing bone loss at the spine and hip after a heart transplant. In this study, people who have had a successful heart transplant will receive either active alendronate and a "dummy pill" instead of calcitriol, or active calcitriol and a dummy pill instead of alendronate for the first year after their transplant, starting within 1 month after transplant surgery. We will measure bone density in the hip and spine at the start of the study and after 6 and 12 months, and will also check for broken bones in the spine. This research should lead to ways of preventing this crippling form of osteoporosis.
NCT00000412 ↗	Osteoporosis Prevention After Heart Transplant	Completed	Columbia University	Phase 3	1997-09-01	During the first year after a heart transplant, people often rapidly lose bone from their spine and hips. About 35 percent of people who receive heart transplants will suffer broken bones during the first year after transplantation. This study will compare the safety and effectiveness of the drug alendronate (Fosamax) and the active form of vitamin D (calcitriol) in preventing bone loss at the spine and hip after a heart transplant. In this study, people who have had a successful heart transplant will receive either active alendronate and a "dummy pill" instead of calcitriol, or active calcitriol and a dummy pill instead of alendronate for the first year after their transplant, starting within 1 month after transplant surgery. We will measure bone density in the hip and spine at the start of the study and after 6 and 12 months, and will also check for broken bones in the spine. This research should lead to ways of preventing this crippling form of osteoporosis.
NCT00427037 ↗	Cholecalciferol (Vitamin D3) Therapy in Chronic Kidney Disease (CKD) Subjects	Completed	Atlanta VA Medical Center	N/A	2005-12-01	This is a 12 week pilot and feasibility study with an enrollment goal of 30 subjects. Half of the subjects will be randomized to vitamin D3 and the other half will receive a placebo. Subjects will be referred from the nutrition or renal clinic at Emory. CKD stage 3 and 4 patients will be eligible for participation if they have been determined to have vitamin D deficiency and are not on treatment with vitamin D or vitamin D analogues. Subjects will sign an informed consent form after reviewing the protocol in detail with the principal investigator. A questionnaire would collect information about dietary vitamin D intake, sunlight exposure, and any symptoms of vitamin D deficiency. The subject will have baseline levels of serum vitamin D (25-hydroxyvitamin D), parathyroid hormone (PTH), serum calcium and phosphate, creatinine and other markers of bone turnover. The questionnaires and the blood draws would be repeated on the 6th and 12th week of the study. Subjects will be given 12 pills of each containing either 50,000 IU vitamin D or placebo and asked to take one pill a week. They would be scheduled to return to the clinic after 6 weeks and blood measurements would be repeated. Subjects will be asked to revisit for their final visit at the 12th week when they would have their last blood draw and assessment.

Clinical Trial Conditions for ROCALTROL

Condition Name

Condition Name for ROCALTROL
Intervention	Trials
Vitamin D Deficiency	4
Chronic Kidney Disease	4
Secondary Hyperparathyroidism	3
Hypocalcemia	2

Condition MeSH

Condition MeSH for ROCALTROL
Intervention	Trials
Kidney Diseases	8
Renal Insufficiency, Chronic	7
Hyperparathyroidism	5
Hyperparathyroidism, Secondary	4

Clinical Trial Locations for ROCALTROL

Trials by Country

Trials by Country for ROCALTROL
Location	Trials
United States	34
China	5
Russian Federation	1
Switzerland	1
India	1

Trials by US State

Trials by US State for ROCALTROL
Location	Trials
New York	5
Alabama	2
Virginia	2
California	2
Illinois	2

Clinical Trial Progress for ROCALTROL

Clinical Trial Phase

Clinical Trial Phase for ROCALTROL
Clinical Trial Phase	Trials
Phase 4	8
Phase 3	3
Phase 2	4

Clinical Trial Status

Clinical Trial Status for ROCALTROL
Clinical Trial Phase	Trials
Completed	16
Terminated	4
Not yet recruiting	2

Clinical Trial Sponsors for ROCALTROL

Sponsor Name

Sponsor Name for ROCALTROL
Sponsor	Trials
Columbia University	2
National Cancer Institute (NCI)	2
Roswell Park Cancer Institute	2

Sponsor Type

Sponsor Type for ROCALTROL
Sponsor	Trials
Other	36
Industry	6
NIH	4

ROCALTROL Market Analysis and Financial Projection

Last updated: May 2, 2026

Rocaltrol (calcitriol) — Clinical Trials Update, Market Analysis, and Projection

Rocaltrol (calcitriol) is an established active vitamin D analog with a long commercial history and a mature, generic-driven market structure. Current patent protection is not a primary driver of market outcomes; demand is driven by diagnosis incidence, prescribing inertia, reimbursement, and substitution among calcitriol and other vitamin D analogs (alfacalcidol, paricalcitol, doxercalciferol). Clinical-trial activity centered on calcitriol continues to skew toward comparative effectiveness, dosing strategies, and renal and mineral-bone disorder endpoints, but the phase landscape is not indicative of a near-term “new product cycle” driven by a brand-new calcitriol platform.

What does the clinical trials landscape show for Rocaltrol (calcitriol)?

Trial types and typical endpoints in calcitriol research

Calcitriol clinical work generally clusters around:

• CKD-MBD management using serum calcium, phosphorus, PTH reduction, and biochemical control rates as primary/major endpoints
• Comparative effectiveness against other vitamin D analogs (and dosing frequency differences)
• Safety characterization focused on hypercalcemia/hyperphosphatemia incidence and need for dose interruptions

Phase distribution and development signal

Rocaltrol is not positioned as a late-stage investigational “platform” in the public pipeline. Instead, calcitriol studies tend to:

• Re-test established regimens in contemporary practice
• Provide subgroup or comparative data within CKD-MBD care pathways
• Support label-adjacent refinements rather than create a new commercial lifecycle

Practical reading of “trial activity” for a mature molecule

For investors and R&D planners, the key implication is that trial publications and registry entries around calcitriol do not reliably translate into near-term market expansion versus competing vitamin D analogs. When calcitriol appears in trials, it typically competes on:

• Biochemical control performance
• Safety profile relative to alternatives
• Cost and formulary placement

Selected clinical evidence references (high-level)

The calcitriol clinical evidence base is anchored by CKD-MBD and hypoparathyroidism management literature and clinical practice guidance, including KDIGO recommendations emphasizing monitoring and individualized dosing. KDIGO’s renal bone and mineral guidance frames vitamin D analog selection and monitoring for calcium and phosphorus balance. (Source: KDIGO 2017 update [1])

How is the Rocaltrol market structured today?

Product identity and competitive category

• Rocaltrol is calcitriol (active vitamin D), used for conditions including hypocalcemia due to hypoparathyroidism and CKD-related mineral and bone disorder management under established indications (where applicable by region).
• The competitive set includes other vitamin D receptor activators and analogs, such as:
  • Paricalcitol
  • Doxercalciferol
  • Alfacalcidol
• Generic calcitriol is a material pressure point in price and volume.

Demand drivers

The category demand is anchored to:

• CKD prevalence and progression (biochemical derangement management)
• Hypoparathyroidism prevalence and long-term maintenance therapy
• Formulary and payer preference for oral vitamin D analogs based on total cost of care and monitoring burden

Pricing and distribution realities

For an established calcitriol molecule:

• Brand differentiation is limited once generics are established.
• Market shares shift based on formulary tiering, patient-specific tolerability, and prescriber familiarity.
• Adoption of higher-priced analogs (for example, selective analogs like paricalcitol in some settings) depends on relative safety outcomes and cost-effectiveness framing in local health systems.

What does the evidence say about positioning calcitriol versus alternatives?

Safety and monitoring remain the core differentiators

Vitamin D therapy is limited by hypercalcemia risk. Clinical management focuses on:

• Calcium and phosphorus monitoring cadence
• Dose interruption and restart pathways
• Adjusting therapy in response to biochemical changes

KDIGO’s framework highlights monitoring and individualization as core components of CKD-MBD management. (Source: KDIGO 2017 update [1])

Clinical practice effect: analog choice follows risk and payer preference

In practice, clinicians often choose between:

• Less selective options (calcitriol itself) when low cost and familiarity matter
• Selective vitamin D analogs where their perceived safety profile supports adoption This dynamic tends to dampen “brand growth” for Rocaltrol but sustains category volume overall.

What market projections are supportable for Rocaltrol through 2029-2030?

Base-case projection logic for mature calcitriol brands

Because calcitriol is mature and faces generic competition, projections typically follow:

1. Category growth tracks CKD and chronic endocrine disease prevalence
2. Share shifts within the vitamin D analog class
3. Pricing declines follow generic penetration and payer bargaining

Market outlook scenarios (directional, business-useful)

Base case (most likely):

• Modest unit growth driven by epidemiology
• Flat-to-down branded revenue due to generic substitution and price compression
• Share stability or gradual erosion versus selective analogs in formularies that favor safety and dosing convenience

Low case (downside):

• Faster brand erosion if more payers tighten preferred drug lists toward selective analogs or if generic pricing compresses branded margins further
• Reduced branded uptake as clinicians standardize on alternatives

High case (upside):

• Local payer concessions or formulary exceptions sustain branded volumes
• Prescriber preference holds in specific subpopulations with established regimen control

What this implies for investment and R&D planning

• For pipeline-based investment, calcitriol itself is not a new “growth vector.” It is a mature category asset.
• The commercial upside is more likely to come from platform development in vitamin D analogs or combination strategies that improve safety and monitoring efficiency rather than brand extension of calcitriol.

Key competitive map for calcitriol therapy (strategic context)

Dimension	Rocaltrol (calcitriol)	Competitive analogs (examples)	What drives selection
Molecule type	Active vitamin D (calcitriol)	Vitamin D receptor activators (selective or prodrug forms)	Safety balance and monitoring burden
Main clinical constraints	Hypercalcemia risk	Class constraints, often different risk profiles	Serum calcium/phosphorus control
Pricing dynamics	Brand compressed by generic calcitriol	Paricalcitol and others often higher unit cost	Formulary tiering and reimbursement
Where share moves	Between CKD-MBD and hypoparathyroidism care pathways	Within CKD-MBD analog selection	Prescriber experience and guideline adoption
Growth behavior	Mature, incidence-linked	Can take share based on perceived safety	Payer policies and comparative outcomes

What should decision-makers watch next for Rocaltrol?

Signals that matter more than new trials

For a mature calcitriol brand, the highest-impact “updates” are typically:

• Formulary changes that shift preferred therapy within vitamin D analogs
• Reimbursement policy changes that alter relative net prices and patient access
• Evidence interpretations that change perceived hypercalcemia risk tradeoffs
• KDIGO or local guideline updates affecting CKD-MBD vitamin D analog positioning (monitoring and dosing principles) (Source: KDIGO 2017 update [1])

Practical market monitoring checklist

• Track payer preferred lists for CKD-MBD vitamin D analogs
• Monitor generic calcitriol pricing trends by market
• Watch comparative studies that include safety signals relevant to dose-limiting hypercalcemia risk
• Review guideline updates and evidence reviews referencing active vitamin D analogs and monitoring approaches (Source: KDIGO 2017 update [1])

Key Takeaways

• Rocaltrol (calcitriol) operates in a mature vitamin D analog category where generic competition and formulary dynamics dominate revenue outcomes.
• Public clinical trial activity is best read as ongoing optimization and comparative evidence within CKD-MBD and mineral balance management, not as a new product lifecycle driver. KDIGO’s CKD-MBD framework continues to anchor clinical decision-making around monitoring and individualized dosing. (Source: KDIGO 2017 update [1])
• Market growth is likely incidence-led (CKD and chronic endocrine disease prevalence) with branded revenue remaining flat-to-down due to substitution and price compression.
• Upside is more plausible from payer access stability and localized formulary preference than from a near-term clinical development breakthrough for calcitriol itself.

FAQs

1) Is Rocaltrol expected to have major late-stage clinical development milestones?

Rocaltrol’s clinical narrative is dominated by mature use and comparative/optimization studies rather than a near-term late-stage “new evidence” cycle that changes commercial positioning. The clinical framework remains anchored by CKD-MBD guidance emphasizing monitoring and individualized dosing. (Source: KDIGO 2017 update [1])

2) What endpoints typically decide vitamin D analog utility in trials?

Trials commonly use serum calcium, phosphorus, and PTH changes, with safety endpoints centered on hypercalcemia and hyperphosphatemia incidence and dose interruption rates.

3) What most influences branded calcitriol performance in the market?

Net price after payer contracting and generic substitution, along with formulary tier placement versus selective vitamin D analogs.

4) How does KDIGO shape calcitriol use?

KDIGO’s CKD-MBD guidance emphasizes monitoring of calcium/phosphorus balance and individualized therapy selection rather than a one-size-fits-all vitamin D analog approach. (Source: KDIGO 2017 update [1])

5) Is growth expected to come from CKD incidence?

Yes. Category demand tracks CKD-related mineral disorder prevalence, but branded calcitriol revenue growth is likely limited by generic pricing and internal class substitution.

---

References

[1] Kidney Disease: Improving Global Outcomes (KDIGO). (2017). KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). KDIGO. https://kdigo.org/guidelines/ckd-mbd/